Streptococcus pyogenes, also known as Group A Streptococcus (GAS), causes a wide
variety of clinical manifestations. An effective GAS vaccine would significantly reduce …

Background: Group A Streptococcus (GAS) is a serious human pathogen and effective
vaccines are lacking. Two major vaccine targets are the M-protein and T-antigen, however …

Group A Streptococcus (GAS), or Streptococcus pyogenes, is a gram-positive bacterium that
extensively colonises within the human host. GAS is responsible for causing a range of …

Group A streptococcus (GAS) species are responsible for a broad spectrum of human
diseases, ranging from superficial to invasive infections, and are associated with …

Background. Despite the significant burden of disease associated with infection by group A s
treptococcus (GAS), little is known about the human immune response to GAS antigens after …

Currently there is no commercial Group A Streptococcus (GAS; S. pyogenes) vaccine
available. The development of safe GAS vaccines is challenging, researchers are …

Group A Streptococcus (GAS) is a major human pathogen for which there is no licensed
vaccine. To protect against infection, a strong systemic and mucosal immune response is …

Streptococcus pyogenes, commonly referred to as group A streptococcus (GAS), colonizes
the epithelial surfaces of the upper respiratory tract and the skin, where it causes a myriad of …

Abstract Pili of Group A Streptococcus (GAS) are surface-exposed structures involved in
adhesion and colonisation of the host during infection. The major protein component of the …

Research into a vaccine against the human pathogen group A streptococcus (GAS) has
been ongoing for many years. The majority of this research has focussed on the M-protein …